https://stockhub.co/index.php?action=history&feed=atom&title=Brii_Biosciences_LimitedBrii Biosciences Limited - Revision history2026-05-28T02:33:03ZRevision history for this page on the wikiMediaWiki 1.43.5https://stockhub.co/index.php?title=Brii_Biosciences_Limited&diff=67222&oldid=prev95.149.241.133: Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic..."2022-09-21T22:45:55Z<p>Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic..."</p>
<p><b>New page</b></p><div>== Summary<ref>Source: Yahoo Finance.</ref> ==<br />
<br />
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.<br />
<br />
== References and notes == <br />
[[Category:Thesis]]<br />
__INDEX__</div>95.149.241.133